Evidence map›Paper›PMID 39030620›Full record

ArticleTrials2024

Translated and culturally adapted internet-delivered cognitive therapy for social anxiety disorder in Japanese clinical settings: study protocol for a randomised controlled trial.

Naoki Yoshinaga, Graham R Thew, Yuta Hayashi, Hiroki Tanoue, Michikazu Nakai, David M Clark

Abstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Naoki YoshinagaSchool of Nursing, Faculty of Medicine, University of Miyazaki, 5200, Kihara, Kiyotake, Miyazaki City, 889-1692, Japan. naoki-y@med.miyazaki-u.ac.jp.
Graham R ThewDepartment of Experimental Psychology, University of Oxford, The Old Rectory, Paradise Square, Oxford, OX1 1TW, UK. graham.thew@psy.ox.ac.uk.ORCID http://orcid.org/0000-0003-2851-1315
Yuta HayashiDepartment of Nursing, Graduate School of Health Sciences, Kobe University, 7-10-2 Tomogaoka, Suma-Ku, Kobe, Hyogo, 654-0142, Japan.
Hiroki TanoueSchool of Nursing, Faculty of Medicine, University of Miyazaki, 5200, Kihara, Kiyotake, Miyazaki City, 889-1692, Japan.
Michikazu NakaiDivision of Data Management, Department of Social Medicine, Faculty of Medicine, University of Miyazaki, 5200, Kihara, Kiyotake, Miyazaki City, 889-1692, Japan.
David M ClarkDepartment of Experimental Psychology, University of Oxford, The Old Rectory, Paradise Square, Oxford, OX1 1TW, UK.

Funding

Daiwa Anglo-Japanese Foundation 13068/13890Japan Society for the Promotion of Science London 20H01769Wellcome Trust 200796Wellcome Trust 200796/Z/16/Z
6 · The paper itself

Abstract

backgroundCognitive therapy for social anxiety disorder (CT-SAD) has extensive empirical support and is recommended in several national guidelines. However, ensuring access to evidence-based psychological therapies such as CT-SAD remains a global challenge. An internet-delivered version of this treatment protocol (iCT-SAD) has recently been developed in the UK as a way to overcome this challenge, demonstrating comparable outcomes to face-to-face CT-SAD whilst requiring less therapist time per client. Initial findings also suggest its cross-cultural transferability, but the previous studies in other cultural settings used the English language programme and only included English-fluent participants as a second language. It is not yet known what outcomes can be achieved once the programme has been translated and adapted for a different cultural context. Therefore, this trial aims to evaluate the clinical efficacy of Japanese iCT-SAD when combined with treatment as usual (TAU) in clients with SAD.

methodsThis two-arm, parallel-group, superiority randomised controlled trial will recruit 60 Japanese participants with SAD, randomly assigning them to either Japanese iCT-SAD + TAU or TAU alone at a ratio of 1:1. The primary outcome measure is the self-report Liebowitz Social Anxiety Scale, and secondary.outcomes include other measures of social anxiety symptoms and processes, general mood and functioning, and response to treatment. We will also assess treatment acceptability and gather participant feedback. Assessments will take place at baseline (week 0), mid-treatment (week 8), and post-treatment (week 15), with a further 3-month follow-up (week 27) for the iCT-SAD + TAU arm. The primary analyses will be conducted on an intent-to-treat basis, comparing the primary and secondary outcome measures between groups using linear mixed-effect models, along with additional mediation analysis. DISCUSSION: Investigating the efficacy of translated and culturally adapted iCT-SAD in different cultural contexts is an important step in evaluating the global reach of internet interventions. This trial will provide valuable insights into the effects of iCT-SAD combined with usual care, and how this treatment could be delivered in routine clinical settings in Japan.

trial registrationInternational Standard Randomized Controlled Trials (ISRCTN), ISRCTN82859645, registered on January 19, 2024. UMIN Clinical Trials Registry (UMIN-CTR), UMIN000052702, registered on November 6, 2023.

Indexed as

Cognitive Behavioral TherapyPhobia, SocialAdolescentAdultCulturally Competent CareEast Asian PeopleEquivalence Trials as TopicFemaleHumansInternetInternet-Based InterventionJapanMaleMiddle AgedRandomized Controlled Trials as TopicTranslatingClinical trial protocolCognitive behavioural therapyCognitive therapyCultural adaptationInternet interventionsJapanRandomised controlled trialSocial anxiety disorder

Identifiers

PMID39030620
PMCPMC11264708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.